Pfizer Inc ((PFE)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Pfizer Inc. is conducting a Phase 2A clinical study titled A PHASE 2A MULTICENTER, OBSERVER-BLINDED, RANDOMIZED 2 ARM STUDY TO INVESTIGATE PHARMACOKINETICS, SAFETY, TOLERABILITY AND EFFICACY OF INTRAVENOUS AZTREONAM-AVIBACTAM ± METRONIDAZOLE COMPARED TO BEST AVAILABLE THERAPY (BAT) IN PEDIATRIC PARTICIPANTS 9 MONTHS TO LESS THAN 18 YEARS OF AGE WITH SERIOUS GRAM-NEGATIVE BACTERIAL INFECTIONS INCLUDING COMPLICATED INTRA-ABDOMINAL INFECTION. The study aims to evaluate the pharmacokinetics, safety, and efficacy of Aztreonam-Avibactam (ATM-AVI) in pediatric patients with serious gram-negative infections, offering insights into potential treatment improvements for this vulnerable population.
The study is testing the drugs Aztreonam and Avibactam, administered intravenously, targeting resistant gram-negative bacterial infections. These drugs are intended to provide an effective treatment alternative for serious infections in children, potentially improving outcomes compared to the best available therapy (BAT).
This interventional study is randomized with a parallel assignment model. It is open-label with a single-blinded observer, focusing on treatment as the primary purpose. Participants are allocated to receive either ATM-AVI or BAT, with the study aiming to assess the drugs’ safety and effectiveness.
The study began on April 18, 2023, and is currently recruiting participants. The primary completion date is yet to be determined, with the last update submitted on August 4, 2025. These dates are crucial for tracking the study’s progress and anticipating results.
This clinical study update from Pfizer could influence investor sentiment and stock performance, as successful outcomes may enhance Pfizer’s market position in pediatric infectious disease treatment. Competitors in the pharmaceutical industry may also be closely monitoring these developments, given the potential market impact.
The study is ongoing, with further details available on the ClinicalTrials portal.